Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

Nature Medicine

Volumn 5, Issue 5, 1999, Pages 526-534

  Robinson, Harriet L ^a   Montefiori, David C ^b   Johnson, R Paul ^c   Manson, Kelledy H ^d   Kalish, Marcia L ^e   Lifson, Jeffrey D ^f   Rizvi, Tahir A ^g   Lu, Shan ^h   Hu, Shiu Lok ⁱ   Mazzara, Gail P ^j   Panicali, Dennis L ^j   Herndon, James G ^a   Glickman, Rhona ^c   Candido, Maria A ^a   Lydy, Shari L ^a   Wyand, Michael S ^d   McClure, Harold M ^a  

^a EMORY UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d GTC Mason Laboratories   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j Therion Biologics Corporation   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; ENVELOPE PROTEIN; FREUND ADJUVANT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ARTICLE; CELLULAR IMMUNITY; FOWLPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INTRADERMAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS RECOMBINANT;

EID: 0032920019     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/8406     Document Type: Article

References (49)

1. The World Health Organization in AIDS Epidemic Update (Joint United Nations Programme on HIV/AIDS and the World Health Organization, Geneva, 1998).
2. Moore, J.P. & Ho, D.D. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS 9, S117-136 (1995).
3. Burton, D.R. & Moore, J.P. Why do we not have an HIV vaccine and how can we make one? Nature Med. 4, 495-498 (1998).
4. Rosenberg, E.S. et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278, 1447-1450 (1997).
5. Schacker, T.W., Hughes, J.P., Shea, T., Coombs, R.W. & Corey, L. Biological and virologic characteristics of primary HIV infection. Ann. Intern. Med. 128, 613-620 (1998).
6. Finzi, D. & Silliciano, R.F. Viral dynamics in HIV-1 infection. Cell 93, 665-671 (1998).
7. Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K. & Desrosiers, R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1941 (1992).
8. Baba, T.W. et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820-1825 (1995).
9. Ruprecht, R.M., Baba, T.W. & Liska, V. Attenuated HIV vaccine: caveats. Science 271, 1790-1792 (1996).
10. Mascola, J.R. et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173, 340-348 (1996).
11. Connor, R.I. et al. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72, 1552-1576 (1998).
12. Graham, B.S. et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J. Infect. Dis. 177, 310-319 (1998).
13. Moss, B. Recombinant DNA virus vectors for vaccination. Semin. Immunol. 2, 317-327 (1990).
14. Tartaglia, J. et al. Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res. Hum. Retroviruses 14 Suppl 3, S291-298 (1998).
15. Stott, J. & Hu, S.L AIDS 1998. Vaccines and immunology: overview. AIDS 12, S95-96 (1998).
16. Hu, S.-L. et al. in Transmembrane Protein and Core Antigens in Protection against SIV Infection (eds. Chanock, R.M., Brown, F., Ginsberg, H.S. & Norrby, E.) 167-173 (Cold Spring Harbor Laboratory Press, New York, 1995).
17. Robinson, H.L. & Torres, C.A. DNA vaccines. Semin. Immunol. 9, 271-283 (1997).
18. Donnelly, J.J., Ulmer, J.B., Shiver, J.W. & Liu, M.A. DNA vaccines. Annu. Rev. Immunol. 15, 617-648 (1997).
19. Boyer, J.D. et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nature Med. 3, 526-532 (1997).
20. Letvin, N.L. et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc. Natl. Acad. Sci. USA 94, 9378-9383 (1997).
21. Li, J., Lord, C.I., Haseltine, W., Letvin, N.L. & Sodroski, J. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. Acquir. Immune Detic. Syndr. 5, 639-646 (1992).
22. Li, J.T. et al. Persistent infection of macaques with simian-human immunodeficiency viruses. J. Virol.69, 7061-7067 (1995).
23. Reimann, K.A. et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70, 6922-6928 (1996).
24. Lu, S. et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70, 3978-3991 (1996).
25. Fynan, E.F. et al. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA 90, 11478-11482 (1993).
26. Pertmer, T.M. et al. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 13, 1427-1430 (1995).
27. Klaniecki, J. et al. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus. AIDS Res. Hum. Retroviruses 7, 791-798 (1991).
28. Jenkins, S. et al. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res. Hum. Retroviruses 7, 991-998 (1991).
29. Johnson, R.P. et al. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J. Virol. 71, 7711-8 (1997).
30. Richmond, J.F. et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J. Virol. 72, 9092-9100 (1998).
31. Suryanarayana, K., Wiltrout, T.A., Vasquez, G.M., Hirsch, V.M. & Lifson, J.D. Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. AIDS Res. Hum. Retroviruses 14, 183-189 (1998).
32. Wyand, M.S., Manson, K.H., Garcia-Moll, M., Montefiori, D. & Desrosiers, R.C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70, 3724-3733 (1996).
33. Montefiori, D.C. & Evans, T.G. Toward an HIV-type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res. and Hum. Retroviruses 15, 689-698 (1999).
34. Yang, O.O. et al. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc. Natl. Acad. Sci. USA 94, 11478-11483 (1997).
35. Levy, J.A., Mackewicz, C.E. & Barker, E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol. Today 17, 217-224 (1996).
36. Feltquate, D.M., Heaney, S., Webster, R.C. & Robinson, H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158, 2278-84 (1997).
37. O'Garra, A. & Murphy, K. Role of cytokines in determining T-lymphocyte function. Curr. Opin. Immunol. 6, 458-66 (1994).
38. Seder, R.A. & Paul, W.E. Acquisition of lymphokine-producing phenotype by CD4+ T cells. Annu. Rev. Immunol. 12, 635-673 (1994).
39. Dittmer, U., Brooks, D.M. & Hasenkrug, K.J. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection. Nature Med. 5, 189-193 (1999).
40. Johnson, R.P. Live attenuated AIDS vaccines: hazards and hopes. Nature Med 5, 154-155 (1999).
41. Schneider, J. et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 4, 397-402 (1998).
42. Sedegah, M. et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 95, 7648-7653 (1998).
43. Kent, S.J. et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of conseculive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72, 10180-10188 (1998).
44. Polacino, P. et al. Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J. Virol. 73, 618-630 (1999).
45. Gritz, L. et al. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiercy virus type 1 env. J. Virol. 64, 5948-5957 (1990).
46. Andersson, S., Davis, D.L., Dahlback, H., Jornvall, H. & Russell, D.W. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J. Biol. Chem. 264, 8222-8229 (1989).
47. Earl, P.L. et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 68, 3015-3026 (1994).
48. Schochetman, G., Subbarao, S. & Kalish, M.L. in Viral Genome Methods (ed. K.W. Adolph) 25-41 (CRC Press, Boca Raton, 1996).
49. Montefiori, D.C., Robinson, W.E.Jr., Schuffman, S.S. & Mitchell, W.M. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J. Clin. Microbiol. 26, 231-235 (1988).